Tonix Pharmaceuticals (NASDAQ:TNXP) Rating Lowered to “Sell” at Wall Street Zen

Tonix Pharmaceuticals (NASDAQ:TNXP) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tonix Pharmaceuticals in a research note on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold”.

Tonix Pharmaceuticals Stock Performance

Shares of TNXP opened at $12.88 on Friday. The company has a market capitalization of $172.59 million, a PE ratio of -0.90 and a beta of 1.88. The company’s 50 day moving average price is $15.42 and its 200 day moving average price is $18.03. Tonix Pharmaceuticals has a 52 week low of $12.70 and a 52 week high of $69.97.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its earnings results on Thursday, March 12th. The company reported ($3.98) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.16) by ($0.82). The company had revenue of $5.39 million during the quarter, compared to analysts’ expectations of $2.97 million. Tonix Pharmaceuticals had a negative return on equity of 60.15% and a negative net margin of 946.22%. On average, equities analysts forecast that Tonix Pharmaceuticals will post -1762.5 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO Seth Lederman acquired 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 18th. The shares were purchased at an average price of $14.89 per share, for a total transaction of $223,350.00. Following the completion of the acquisition, the chief executive officer owned 15,001 shares of the company’s stock, valued at approximately $223,364.89. This represents a 1,500,000.00% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.03% of the company’s stock.

Institutional Trading of Tonix Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the business. Legal & General Group Plc acquired a new position in shares of Tonix Pharmaceuticals during the 2nd quarter worth $25,000. Ameritas Investment Partners Inc. acquired a new stake in shares of Tonix Pharmaceuticals in the 2nd quarter valued at $28,000. Russell Investments Group Ltd. acquired a new stake in shares of Tonix Pharmaceuticals in the 3rd quarter valued at $29,000. Police & Firemen s Retirement System of New Jersey bought a new stake in Tonix Pharmaceuticals in the second quarter worth $62,000. Finally, State of Wyoming bought a new stake in Tonix Pharmaceuticals in the fourth quarter worth $27,000. 82.26% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Tonix Pharmaceuticals

Here are the key news stories impacting Tonix Pharmaceuticals this week:

• Positive Sentiment: First participant dosed in a Phase 1 investigator‑initiated pharmacodynamic study of TNX‑1900 to assess potential for treating migraine and craniofacial pain; intranasal oxytocin blocks CGRP release in animal models and represents a mechanism distinct from current CGRP drugs, which could broaden Tonix’s pipeline if signals are positive. Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900
• Neutral Sentiment: Multiple outlets (Business Insider, Yahoo Finance, TipRanks) picked up the dosing announcement — that raises visibility and investor attention but the study is early‑stage (pharmacodynamic model), so clinical readouts and commercialization remain uncertain. Tonix Pharmaceuticals Announces First Participant Dosed (Business Insider)
• Negative Sentiment: Zacks Research substantially lowered its near‑term EPS forecasts for Tonix, cutting FY2026 and FY2027 estimates and issuing much larger expected losses per share (e.g., FY2026 now modeled at roughly -$10.52). Those revisions signal analyst concern about cash runway, development timelines and the likelihood of future dilution — a key reason for downward pressure on the stock. What is Zacks Research’s Estimate for TNXP FY2028 Earnings?

About Tonix Pharmaceuticals

Tonix Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system disorders, immunology and rare diseases. The company’s pipeline includes small-molecule and biologic product candidates designed to address conditions such as fibromyalgia, post-traumatic stress disorder (PTSD) and other chronic pain syndromes, as well as vaccines for potential viral and biothreat agents.

Among Tonix’s lead programs is TNX-102 SL, a sublingual formulation of cyclobenzaprine being evaluated for the treatment of fibromyalgia and PTSD.